Drug · DIN 02475200
LYNPARZA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 23, 2018; first marketed May 23, 2018.
- Drug Identification Number (DIN)
- 02475200
- Company (DIN owner)
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Olaparib L01XK01
- Class
- Human
- Record last updated
- July 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| OLAPARIB | 100 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 4, 2018: NOC 20821Supplement to a New Drug Submission (SNDS) · New indication: monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (psr) brca wild type high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy
Other DINs named LYNPARZA
- DIN 02475219 · Marketed
- DIN 02454408 · Cancelled Post Market